Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28974289 | 0.83 | PNMT (0.52) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL28996980 | 0.82 | NISCH (0.41) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL30209730 | 0.81 | ALDH1A1 (0.53) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL29781979 | 0.77 | CFD (0.59) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL30148348 | 0.77 | CFD (0.64) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL17023736 | 0.77 | CFD (0.59) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL12480093 | 0.77 | CFD (0.59) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL30140001 | 0.77 | CFD (0.64) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL10217259 | 0.77 | CFD (0.59) | CFDCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL16397203 | 0.76 | CFD (0.58) | CFDCYP1A2CYP3A4CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | CFD 9/4885CYP1A2 611/4885CYP3A4 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.